US equities |
MU $940.49 ▼-1.33% NVDA $224.74 ▼-1.65% SPCX $152.99 ▼-2.27% SNDK $1,438.04 ▼-2.99% META $751.05 ▼-1.50% AAPL $345.53 ▲+1.25% AMD $586.61 ▼-3.13% TSLA $365.17 ▼-2.68%
FinancialContent

Churchill Capital Corp XI - Class A Ordinary Shares (NQ:CCXI)

10.74 -0.42 (-3.76%)
Delayed Quote Updated: 10:01 AM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Churchill Capital Corp XI - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Agility Robotics and Churchill Capital Corp XI S-4 Registration Statement Declared Effective by SEC in Connection with Proposed Business Combination
From Agility Robotics, Inc.
Via Business Wire
News headline image
The First Pure-Play Humanoid Robot Stock Is About to Go Public. Here's What Investors Need to Know About Agility Robotics. ↗
Like many other up-and-coming companies that are going public specifically because their business and their industry are clearly at a turning point, there's plenty of price-inflating hope here. 
Via The Motley Fool
Topics Artificial Intelligence Electric Vehicles
News headline image
Agility Robotics to Livestream Analyst & Investor Day Today
From Agility Robotics
Via Business Wire
News headline image
Agility Robotics Announces New Directors for Planned Public-Company Board
From Agility Robotics
Via Business Wire
News headline image
Agility to Host Analyst & Investor Day on October 6, 2026
From Agility Robotics
Via Business Wire
News headline image
Agility Robotics to Attend Upcoming Investor Conferences
From Agility Robotics
Via Business Wire
News headline image
Agility Robotics and Churchill Capital Corp XI Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination
From Agility Robotics, Inc.
Via Business Wire
News headline image
Grounded: SpaceX Stumbles as Grok Fails to Ignite ↗
SpaceX shares fell 8% after Nasdaq 100 inclusion as Grok's market share slipped, while Tesla dropped 7% despite a delivery beat, reflecting fading AI-driven valuation premiums. 
Via MarketBeat
Topics Artificial Intelligence
Unusual volume stocks are being observed in Monday's session. ↗
Via Chartmill
Unusual volume stocks in Thursday's session ↗
Via Chartmill
News headline image
Agility Robotics’ SPAC Deal Opens a Rare Door Into Humanoid AI ↗
The CCXI-Agility Robotics SPAC merger will create the first U.S.-listed pure-play humanoid equity, valued at $2.5B, with clients including Amazon and a NVIDIA partnership. 
Via MarketBeat
Topics Artificial Intelligence ETFs
On Wednesday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
These stocks have an unusual volume in today's session ↗
Via Chartmill
News headline image
Agility Robotics to Go Public Through $2.5 Billion Merger with Churchill Capital Corp XI
From Agility Robotics, Inc.
Via Business Wire
News headline image
Two Down With Sanofi Bowing Out From Horizon Buyout Talks, Amgen Agrees To Buy For $116.5/Share ↗
 
Via Benzinga
News headline image
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market ↗
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 
Via Benzinga
News headline image
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
From ChemoCentryx, Inc.
Via GlobeNewswire
News headline image
Biotech Stocks Well-Positioned For The Fourth Quarter ↗
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far. 
Via Talk Markets
News headline image
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From ChemoCentryx, Inc.
Via GlobeNewswire
News headline image
These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022 ↗
We have used the August return data from finviz.com to come up with the five best and worst performing mid-cap stocks in August 2022. 
Via Talk Markets
News headline image
Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year ↗
The biotech run off a June bottom is great — until you realize you could've netted more. 
Via Investor's Business Daily
News headline image
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
News headline image
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI
From Scott+Scott Attorneys at Law LLP
Via Business Wire
News headline image
7 Dow Stocks With Superior Fundamentals ↗
Robust Dow stocks offer attractive deals for patient investors amidst an unstable economic environment 
Via InvestorPlace
News headline image
Healthcare Sector Still Looks Good But Lacks Momentum ↗
The summer rally is over it’s a holiday weekend with low trading volume and bad news is pervasive. A decent jobs report on Friday brought in buyers in early hours until Russia intervened with a Nord... 
Via Talk Markets
News headline image
ChemoCentryx's Return On Capital Employed Insights ↗
According to data from Benzinga Pro, during Q2, ChemoCentryx's (NASDAQ:CCXI) reported sales totaled $11.76 million. Despite a 18.02% increase in earnings, the company posted a loss of $31.65 million. 
Via Benzinga
News headline image
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI
From Scott+Scott Attorneys at Law LLP
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >